REG-Bioventix Plc: Director/PDMR Shareholding <Origin Href="QuoteRef">BVXP.L</Origin>

BioventixAnnouncement

20/10/2017 10:12

Bioventix plc

(“Bioventix” or the “Company”)

Director/PDMR Shareholding

Bioventix plc (BVXP), a UK company specialising in the development and
commercial supply of high-affinity monoclonal antibodies for application in
clinical diagnostics, was notified on 19 October 2017 of the following
transactions in its ordinary shares of 5 pence each (“Ordinary Shares”):

 Director                                       Position                 Ordinary Shares sold  Sale price per Ordinary Share  Ordinary Shares held subsequently  Percentage of issued share capital held subsequently 
 Ian Nicholson and Persons Closely Associated   Non-Executive Chairman                  5,000                       2400.75p                             18,000                                                  0.4% 
 Peter Harrison and Persons Closely Associated  CEO                                    80,000                       2425.00p                            428,176                                                  8.3% 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

           Details of the person discharging managerial responsibilities / person closely associated                                                                                                                    
 a)        Names                                                                                              Ian Nicholson (Non-Executive Chairman) Catherine Nicholson (PCA with Ian Nicholson) Peter Harrison (CEO)  
           Reason for the Notification                                                                                                                                                                                  
 a)        Position/status                                                                                    See 1(a) above, all are PDMR’s or PCA’s of PDMR’s                                                         
 b)        Initial notification/Amendment                                                                     Initial notification                                                                                      
           Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor                                                                                                
 a)        Name                                                                                               Bioventix plc                                                                                             
 b)        LEI                                                                                                213800225MHX7LZQY108                                                                                      
           Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted            
 a)        Description of the Financial instrument, type of instrument                                        Ordinary shares of 5 pence (“Ordinary Shares”)                                                            
           Identification code                                                                                GB00B4QVDF07                                                                                              
 b)        Nature of the transaction                                                                          In each case, sale of Ordinary Shares                                                                     
 c)        Price(s) and volume(s)                                                                             Ian Nicholson:                                                                                            
 Price(s)  Volume(s)                                                                                          
 2400.75p  2,500                                                                                              
 Price(s)  Volume(s)                                                                                          
 2400.75p  2,500                                                                                              
 Price(s)  Volume(s)                                                                                          
 2425.00p  80,000                                                                                             
 d)        Aggregated information:                                                                            See 4(c)                                                                                                  
 e)        Date of the transaction                                                                            19 October 2017                                                                                           
 f)        Place of the transaction                                                                           London Stock Exchange, AIM Market (XLON)                                                                  

For further information please contact:

 Bioventix plc Peter Harrison                         Chief Executive Officer              Tel: 01252 728 001  
                                                                                                               
 finnCap Ltd Geoff Nash/Simon Hicks Stephen Norcross  Corporate Finance Corporate Broking  Tel: 020 7220 0500  

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce
a suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.



Copyright (c) 2017 PR Newswire Association,LLC. All Rights Reserved